Use of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors: Indications and complications

Journal of the American Osteopathic Association

Volumn 102, Issue 9, 2002, Pages 487-489

  Pascucci, Richard A ^a  

^a PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

Arthritis; Cardiovascular risk; Celecoxib; Cyclooxygenase 2 inhibitors COX 2 inhibitors ; nonsteroidal anti inflammatory drugs NSAIDs ; Pain; Rofecoxib; Valdecoxib

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; INDOMETACIN; NAPROXEN; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; ROFECOXIB;

ARTICLE; ASEPTIC MENINGITIS; CARDIOVASCULAR RISK; DRUG APPROVAL; DRUG INDICATION; DRUG SAFETY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; INHIBITION KINETICS; KIDNEY DISEASE; MORBIDITY; OSTEOARTHRITIS; PATIENT COMPLIANCE; PATIENT MONITORING; PRESCRIPTION; RHEUMATOID ARTHRITIS; STOMACH ULCER; UNITED STATES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DIGESTIVE SYSTEM; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0036739722     PISSN: 00986151     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Whelton A, Stout RL, Spilman PS, Klassen DK. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. A prospective, randomized, crossover comparison. Ann Intern Med. 1990;112:568-576.
2. Vane JR. Introduction: mechanism of action of NSAIDs. B J Rheumatol. 1996; 35(suppl 1):1-3.
3. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340:1888-1899. [Published erratum in: N Engl J Med. 1999:341:548.]
4. Graumlich JF. Preventing gastrointestinal complications of NSAIDs. Risk factors, recent advances, and latest strategies. Postgrad Med. 2001;109(5):117-120, 123-128.
5. Guidelines for Reviewers of Rheumatic Disease Care ACR (CORE). Atlanta, Ga: American College of Rheumatology; 1989.
6. Vane JR, Bakhle S, Botting RM. Cyclooxygenases 1 and 2. Ann Rev Pharmacol Toxicol. 1998;38:97-120
7. Spangler, RS. Cyclooxygenase 1 and 2 in Rheumatic Disease: Implications for Nonsteroidal Anti-inflammatory Drug Therapy. Semin Arthritis Rheum. 1996;26:435-446.
8. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247-1255.
9. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000; 343:1520-1528.
10. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433-442.
11. Catella-Lawson F, Reilly M, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809-1817.
12. Crofford L. Rational use of analgesic and antiinflammatory drugs. N Engl J Med. 2001;345:1844-1846.
13. Bonnel RA, Villalba ML, Karwoski CB, Beitz J. Aseptic meningitis associated with rofecoxib. Arch Intern Med. 2002;162:713-715.
14. Simon LS, Mills JA. Drug therapy: Nonsteroidal antiinflammatory drugs (second of two parts). N Engl J Med. 1980;302:1237-1242.
15. In't Veld BA, Ruitenberg A, Hofman A, Launer U, van Duijn CM, Stijnen T, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001;345:1515-1521.
16. Chau I, Cunningham D. Cyclooxygenase inhibition in cancer-A blind alley or a new therapeutic reality? [Editorial]. N Engl J Med. 2002;346:1085-1087.